Clinical Trials
11 trialsNCT06295731 2026-05-08
HexAgon-HN
Inhibrx Biosciences, Inc
Phase 2/3 Active not recruiting
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT00743262 2023-07-25
Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis
Atos Medical AB
Phase 1/2 Completed
NCT05830240 2023-04-26
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Unknown
NCT03254927 2023-04-03
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Celldex Therapeutics
Phase 2 Terminated
NCT04129320 2022-02-08
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
MacroGenics
Phase 2/3 Withdrawn
NCT01045057 2021-06-11
Clinical Feasibility of New Tracheoesophageal Puncture Set
Atos Medical AB
Phase NA Completed
NCT00661570 2017-03-10
Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice Prosthesis
Atos Medical AB
Phase NA Terminated
NCT03039465 2017-02-01
TEP
HealthCare Global Enterprise Ltd.
Phase NA Unknown
NCT00080028 2007-05-08
Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
Pharmacyclics LLC.
Phase 1 Terminated